SUMATRIPTAN SUCCINATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H21N3O2S.C4H6O4
Molecular Weight	413.488
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1

InChI

InChIKey=PORMUFZNYQJOEI-UHFFFAOYSA-N

InChI=1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula	C14H21N3O2S
Molecular Weight	295.4
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020080s049lbl.pdf

Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist indicated for acute treatment of migraine with or without aura in adults. Sumatriptan is structurally similar to serotonin (5-HT), and is a 5-HT receptor (types 5-HT1D and 5-HT1B) agonist. The specific receptor subtypes it activates are present on the cranial arteries and veins. Acting as an agonist at these receptors, sumatriptan reduces the vascular inflammation associated with migraines. The specific receptor subtype it activates is present in the cranial and basilar arteries. Activation of these receptors causes vasoconstriction of those dilated arteries. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. It is most effective taken early after the start of the pain. Injected sumatriptan is more effective than other formulations. Large doses of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to greenish-black, due to the integration of sulfur into the hemoglobin molecule. Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (V-Fib).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin 1a (5-HT1a) receptor 177 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8568822	Agonist 2752	330.0 nM [IC50]
Serotonin 1b (5-HT1b) receptor 45 Target ID: CHEMBL1898 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9871581	Agonist 2752	38.3 nM [EC50]
Serotonin 1f (5-HT1f) receptor 15 Target ID: CHEMBL1805 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11708905	Agonist 2752	35.0 nM [EC50]
Serotonin 1d (5-HT1d) receptor 53 Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14643336	Agonist 2752	5.3 nM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Migraine with aura 11 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020080s049lbl.pdf	Primary	Approved 8583	IMITREX Approved Use Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date 1997
Migraine without aura 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020080s049lbl.pdf	Primary	Approved 8583	IMITREX Approved Use Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date 1997
Cluster headache 10 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020080s049lbl.pdf	Primary	Approved 8583	IMITREX Approved Use Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date 1997

C_max

Value	Dose	Analyte	Population
77 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
42 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
80 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
194 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
90 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
112 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
144 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
105 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
239 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
44 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
83 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
158 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
380 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
476 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
590 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SUMATRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
200 mg 1 times / month multiple, oral Dose: 200 mg, 1 times / month Route: oral Route: multiple Dose: 200 mg, 1 times / month Sources: https://pubmed.ncbi.nlm.nih.gov/1313746/	unhealthy, 18 - 65 years Health Status: unhealthy Age Group: 18 - 65 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1313746/	Sources: https://pubmed.ncbi.nlm.nih.gov/1313746/
300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20051552/	unhealthy, 35 years Health Status: unhealthy Age Group: 35 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20051552/	Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/20051552/
6 mg 2 times / day multiple, subcutaneous Overdose Dose: 6 mg, 2 times / day Route: subcutaneous Route: multiple Dose: 6 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11531904/	unhealthy, 36 years Health Status: unhealthy Age Group: 36 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/11531904/	Sources: https://pubmed.ncbi.nlm.nih.gov/11531904/
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	Other AEs: Abnormal physical sensation, Abnormal physical sensation... Other AEs: Abnormal physical sensation (6%) Abnormal physical sensation (6%) Abnormal physical sensation (6%) Sensation of pressure (8%) Chest tightness of (2%) Throat tightness (3%) Pain (1%) Pressure (3%) Vertigo (2%) Malaise and fatigue (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf

AEs

AE	Significance	Dose	Population
Ischemic colitis	1 patient Disc. AE	300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20051552/	unhealthy, 35 years Health Status: unhealthy Age Group: 35 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20051552/
Pain	1%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Chest tightness of	2%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Vertigo	2%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Malaise and fatigue	3%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Pressure	3%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Throat tightness	3%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Abnormal physical sensation	6%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Abnormal physical sensation	6%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Abnormal physical sensation	6%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf
Sensation of pressure	8%	100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MATE1 415 P-gp 1741	OCT1 393 P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/28283434/	weak
MATE1 416	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23241029/	yes [IC50 6.7 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12438524/	no
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12017403/	no	weak (co-administration study) Comment: coadministered with clarithromycin: mean sumatriptan AUC(infinity) and Cmax values after administration of combination treatment were 9% and 14% higher, respectively Sources: https://pubmed.ncbi.nlm.nih.gov/12017403/
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26659468/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:10650	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10650
ChemicalBook	CB4135041	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4135041
eMolecules	902519	https://www.emolecules.com/cgi-bin/more?vid=902519
ZINC	ZINC000000014360	http://zinc15.docking.org/substances/ZINC000000014360

PubMed

Title	Date	PubMed
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients.	2001-08	11427330
Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats.	2001-06-13	11409721
Effect of rizatriptan in the spectrum of headache.	2001-06	11437904
Sumatriptan can alleviate headaches due to carotid artery dissection.	2001-06	11437896
[Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist].	2001-06	11436516
Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats.	2001-06	11422450
Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.	2001-06	11405809
Recent development in paediatric headache.	2001-06	11371756
Headache and female hormones: what you need to know.	2001-06	11371755
Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons.	2001-06	11353815
Modifications by sumatriptan and acetylcholine of nitric oxide-mediated neurogenic dilatation in dog cerebral arteries.	2001-05-18	11412840
Intracranial hemorrhages associated with sumatriptan.	2001-05-08	11342701
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.	2001-05-01	11301495
Neurogenic inflammation in the context of migraine.	2001-05-01	11301492
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.	2001-05	11422001
Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.	2001-05	11407649
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis.	2001-05	11380643
Oral almotriptan in the treatment of migraine: safety and tolerability.	2001-05	11380642
Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study.	2001-05	11328332
An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system.	2001-05	11323131
Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution.	2001-04-27	11343685
[Aspirin, triptan tablet, nasal spray, injection. Even the most severe migraine capitulates].	2001-04-19	11368000
[Current topics: expectation for new triptans].	2001-04-10	11391915
[Migraine: sumatriptan].	2001-04-10	11391907
[Migraine: selection of therapeutic agents to be applied during its attack].	2001-04-10	11391906
Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group.	2001-04-04	11284463
Managing migraine: strategies for successful patient outcomes.	2001-04	11337821
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine.	2001-04	11318886
Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study.	2001-04	11318884
Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan.	2001-04	11318881
Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder.	2001-04	11313163
Cluster headache: review of the literature.	2001-04	11286443
Fatal cardiac arrhythmia after oral sumatriptan.	2001-03-31	11279937
Relaxation induced by serotonin and sumatriptan in isolated guinea pig gallbladder strips.	2001-03	11426669
Gastric motor effects of triptans: open questions and future perspectives.	2001-03	11401410
Complicated migraine and migraine variants.	2001-03	11332867
Status migrainosus in children and adolescents.	2001-03	11332863
Headaches in children and adolescents: update 2001.	2001-03	11332861
Sumatriptin vs dihydroergotamine: patient preference.	2001-03	11321860
Zolmitriptan versus sumatriptan comparison trial.	2001-03	11264695
[Cluster headache--clinical aspects, pathophysiology and treatment].	2001-02-20	11301614
Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis.	2001-02	11298658
Economic implications of early treatment of migraine with sumatriptan tablets.	2001-02	11293561
Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets.	2001-02	11293559
Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine.	2001-02	11293557
Characterization of 5-HT receptors in the parasitic nematode, Ascaris suum.	2001-02	11272652
Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.	2001	11385269
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.	2001	11327198
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.	2001	11293643
Dramatic headache relief after sumatriptan in a patient with a pituitary macroadenoma.	1999-06	11279924

Patents

Sample Use Guides

In Vivo Use Guide

Migraine Headache. Oral: 25 mg, 50 mg, or 100 mg PO (taken with fluids); Not to exceed 100 mg/dose; additional doses q2hr PRN. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hr; Not to exceed 12 mg SC q24hr Cluster Headache. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hour; Not to exceed 12 mg SC q24hr

Route of Administration: Other

In Vitro Use Guide

The uptake of sumatriptan and other triptans via OCT1 and OCT3 was characterized using HEK293 cells stably transfected to overexpress wild-type OCT1 or OCT3. For measuring the uptake in human hepatocytes, was used cryopreserved human hepatocytes (Gibco Life Technologies, Darmstadt, Germany) obtained from a single donor with two fully active OCT1 alleles. Triptan uptake in OCT1 and OCT3-overexpressing HEK293 cells was measured by incubating the cells with varying concentrations of the substrates in 12-well plates for two minutes at pH 7.4 and 378C. The reaction was stopped with ice-cold buffer, the cells were lysed with 80% acetonitrile, and the intracellularly accumulated triptans were quantified by liquid chromatography coupled to tandem massspectrometry.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:50:17 GMT 2025` Edited by `admin` on `Mon Mar 31 17:50:17 GMT 2025`
Record UNII	J8BDZ68989
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TREXIMET COMPONENT SUMATRIPTAN SUCCINATE

Preferred Name

English

SUMATRIPTAN SUCCINATE

Official Name

English

SUMATRIPTAN SUCCINATE [USP-RS]

Common Name

English

ZEMBRACE SYMTOUCH

Brand Name

English

Sumatriptan succinate [WHO-DD]

Common Name

English

SUMATRIPTAN SUCCINATE [MART.]

Common Name

English

SUMATRIPTAN SUCCINATE [USAN]

Common Name

English

ONZETRA XSAIL

Brand Name

English

SUMATRIPTAN SUCCINATE [USP MONOGRAPH]

Common Name

English

TREXIMET

Common Name

English

SUMATRIPTAN SUCCINATE [EP MONOGRAPH]

Common Name

English

SUMATRIPTAN SUCCINATE [JAN]

Common Name

English

SUMATRIPTAN SUCCINATE [VANDF]

Common Name

English

SUMATRIPTAN SUCCINATE [ORANGE BOOK]

Common Name

English

SUMATRIPTAN GALPHARM

Brand Name

English

NSC-760362

Code

English

1H-INDOLE-5-METHANESULFONAMIDE, 3-(2-(DIMETHYLAMINO)ETHYL)-N-METHYL-, BUTANEDIOATE (1:1)

Systematic Name

English

GR-43175C

Code

English

SUMATRIPTAN SUCCINATE [MI]

Common Name

English

GR 43175C

Code

English

SUMATRIPTAN (AS SUCCINATE)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47794